1
|
Matsuda KM, Yoshizaki A, Kotani H, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S. Serum heat shock protein 27 levels in patients with systemic sclerosis: a possible biomarker of skin sclerosis. J Eur Acad Dermatol Venereol 2020; 35:e157-e159. [PMID: 32805744 DOI: 10.1111/jdv.16885] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 07/28/2020] [Accepted: 08/06/2020] [Indexed: 12/14/2022]
Affiliation(s)
- K M Matsuda
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - A Yoshizaki
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - H Kotani
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - Y Norimatsu
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - A Kuzumi
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - M Fukayama
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - T Fukasawa
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - S Ebata
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - A Yoshizaki-Ogawa
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - Y Asano
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - K Oba
- Department of Biostatistics, School of Public Health, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - S Sato
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
2
|
Satake H, Kotaka M, Ishibashi K, Tsuji Y, Kataoka M, Nakamura M, Nagata N, Sakamoto J, Oba K, Mishima H. 460P Update analysis of phase II study of oxaliplatin based regimen in relapsed colorectal cancer patients treated with oxaliplatin based adjuvant chemotherapy: INSPIRE study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Kotaka M, Ishibashi K, Satake H, Tsuji Y, Kataoka M, Nakamura M, Nagata N, Sakamoto J, Oba K, Mishima H. P-37 phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
4
|
Kazama K, Nakamura M, Tanaka R, Ojima H, Makiyama A, Matsuhashi N, Kagawa Y, Okuda H, Asayama M, Yuasa Y, Negoro Y, Mushiake H, Manaka D, Oba K, Yoshino T, Yoshida K, Maehara Y, Yamazaki K, Oki E, Takahashi T. JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.096] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Ichikawa W, Takeuchi M, Sunakawa Y, Shitara K, Oba K, Yamada Y, Koizumi W, Sakata Y, Furukawa H, Takeuchi M, Fujii M. The relationship between the survival and fixed dosing of S-1 in advanced gastric cancer patients by pooled analysis using individual data from four Japanese randomized phase III trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Akiyoshi T, Toda S, Tominaga T, Oba K, Tomizawa K, Hanaoka Y, Nagasaki T, Konishi T, Matoba S, Fukunaga Y, Ueno M, Kuroyanagi H. Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer. BJS Open 2019; 3:822-829. [PMID: 31832589 PMCID: PMC6887909 DOI: 10.1002/bjs5.50194] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2019] [Accepted: 05/13/2019] [Indexed: 12/17/2022] Open
Abstract
Background There is a lack of large studies focusing on the prognostic significance of lateral lymph node (LLN) metastasis following LLN dissection (LLND) in rectal cancer. The aim of this study was to evaluate the prognostic impact of LLN metastases on survival of patients with advanced low rectal cancer. Methods Consecutive patients with locally advanced, but not metastatic, extraperitoneal rectal cancer treated with neoadjuvant (chemo)radiotherapy plus total mesorectal excision between 2004 and 2015 were included in the study. LLND was performed when pretreatment imaging documented enlarged LLNs (7 mm or greater in size). Localization of nodal metastases and long‐term outcomes were analysed. Kaplan–Meier analysis was used to compare the survival of patients with ypN0 disease with that of patients with mesorectal ypN+/LLN− status and patients with positive LLNs. The Cox proportional hazards model was used to evaluate predictors of disease‐free survival (DFS) and local recurrence. Results A total of 613 patients were included in the study; LLND was performed in 212 patients (34·6 per cent) and 57 (9·3 per cent) had LLN metastasis. Patients with LLN metastasis had improved DFS and local recurrence cumulative incidence rates compared with patients with mesorectal ypN2+/LLN− disease (DFS: P = 0·014; local recurrence: P = 0·006). Although the DFS rate of patients with LLN metastasis was worse than that of patients with ypN0 disease (P < 0·001), the cumulative incidence of local recurrence was similar (P = 0·491). In multivariable analysis, residual LLN metastasis was not an independent predictor of worse DFS or local recurrence. Conclusion LLN metastasis is not an independent predictor of local recurrence or survival. Survival of patients presenting with LLN metastasis after (chemo)radiotherapy was intermediate between that of patients with ypN0 status and those with mesorectal ypN2 positivity.
Collapse
Affiliation(s)
- T Akiyoshi
- Gastroenterological Centre, Department of Gastroenterological Surgery Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan
| | - S Toda
- Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan
| | - T Tominaga
- Gastroenterological Centre, Department of Gastroenterological Surgery Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan
| | - K Oba
- Department of Biostatistics, Graduate School of Medicine The University of Tokyo Tokyo Japan
| | - K Tomizawa
- Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan
| | - Y Hanaoka
- Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan
| | - T Nagasaki
- Gastroenterological Centre, Department of Gastroenterological Surgery Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan
| | - T Konishi
- Gastroenterological Centre, Department of Gastroenterological Surgery Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan
| | - S Matoba
- Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan
| | - Y Fukunaga
- Gastroenterological Centre, Department of Gastroenterological Surgery Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan
| | - M Ueno
- Gastroenterological Centre, Department of Gastroenterological Surgery Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan
| | - H Kuroyanagi
- Department of Gastroenterological Surgery Toranomon Hospital Tokyo Japan
| |
Collapse
|
7
|
Akiyoshi T, Tanaka N, Kiyotani K, Gotoh O, Yamamoto N, Oba K, Fukunaga Y, Ueno M, Mori S. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg 2019; 106:1381-1392. [PMID: 31197828 DOI: 10.1002/bjs.11179] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2018] [Revised: 02/17/2019] [Accepted: 02/18/2019] [Indexed: 12/22/2022]
Abstract
BACKGROUND Accumulating evidence suggests that radiotherapy success has an immune-associated component. The immunogenomic profiles associated with responses to chemoradiotherapy (CRT) were assessed in patients with locally advanced rectal cancer in this study. METHODS CD8+ tumour-infiltrating lymphocyte (TIL) and stromal lymphocyte densities were assessed by immunohistochemistry using pretreatment biopsies from patients with advanced rectal cancer who had preoperative CRT. Whole-exome sequencing and gene expression microarray analysis were conducted to investigate the genomic properties associated with the response to CRT and CD8+ TIL density. Response to CRT was determined based on Dworak tumour regression grade (TRG); tumours with complete (TRG 4) or near-complete (TRG 3) regression were grouped as good responders, and those with TRG 1 as non-responders. RESULTS Immunohistochemical examinations (275 patients) showed that pre-CRT CD8+ TIL density was associated with better response to CRT and improved recurrence-free survival, whereas pre-CRT stromal CD8+ cell density was not associated with either response to CRT or recurrence-free survival. Whole-exome sequencing (74 patients) showed that the numbers of single-nucleotide variations (SNVs) and neoantigens predicted from SNVs were higher in good responders than in non-responders, and these correlated positively with CD8+ TIL density (rS = 0·315 and rS = 0·334 respectively). Gene expression microarray (90 patients) showed that CD8A expression correlated positively with the expression of programmed cell death 1 (PDCD1) (rS = 0·264) and lymphocyte-activation gene 3 (LAG3) (rS = 0·507). CONCLUSION Pre-CRT neoantigen-specific CD8+ T cell priming may be a key event in CRT responses where immune checkpoint molecules could be useful targets to enhance tumour regression.
Collapse
Affiliation(s)
- T Akiyoshi
- Department of Gastroenterological Surgery, Cancer Institute Hospital, Tokyo, Japan
| | - N Tanaka
- Cancer Precision Medicine Centre, Tokyo, Japan
| | - K Kiyotani
- Cancer Precision Medicine Centre, Tokyo, Japan
| | - O Gotoh
- Cancer Precision Medicine Centre, Tokyo, Japan
| | - N Yamamoto
- Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Oba
- Department of Biostatistics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Y Fukunaga
- Department of Gastroenterological Surgery, Cancer Institute Hospital, Tokyo, Japan
| | - M Ueno
- Department of Gastroenterological Surgery, Cancer Institute Hospital, Tokyo, Japan
| | - S Mori
- Cancer Precision Medicine Centre, Tokyo, Japan
| |
Collapse
|
8
|
Kagawa Y, Satake H, Kato T, Oba K, Yasui H, Nakamura M, Watanabe T, Hirata K, Muro K, Komatsu Y, Yoshino T, Yamazaki K, Mishima H, Kotaka M, Tsuji A, Kakeji Y, Oki E, Nagata N, Junichi S. Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Honda M, Matsuda C, Tanaka C, Kondo K, Takahashi T, Kosugi C, Tokunaga Y, Takemoto H, Kim H, Sakamoto J, Oba K, Mishima H. A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy for colorectal cancer: The AIRS study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Takeuchi M, Ichikawa W, Shitara K, Sunakawa Y, Oba K, Koizumi W, Sakata Y, Furukawa H, Takeuchi M, Fujii M. Relation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Kadowaki S, Ishigami H, Muro K, Yoshida S, Hirono Y, Tomita T, Yabusaki H, Kusumoto T, Ota M, Kodera Y, Tsuji Y, Hidemura A, Hachiya O, Oba K, Kitayama J. An exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for peritoneal disseminated gastric cancer patients with inadequate oral intake. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Kozuma K, Kozuma K, Shinozaki T, Kashiwabara K, Oba K, Matsuyama Y. P4566Predictors for angiographic edge restenosis of 2nd generation drug-eluting stents: Integrated angiographic analyses from the post-marketing surveillance studies of everolimus-eluting stents in Japan. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- K Kozuma
- University of Tokyo, Department of Biostatistics, Division of Health Sciences and Nursing Graduate School of Medicine, Tokyo, Japan
| | - K Kozuma
- Teikyo University Hospital, Cardiology, Tokyo, Japan
| | - T Shinozaki
- University of Tokyo, Department of Biostatistics, Division of Health Sciences and Nursing Graduate School of Medicine, Tokyo, Japan
| | - K Kashiwabara
- University of Tokyo, Department of Biostatistics, Division of Health Sciences and Nursing Graduate School of Medicine, Tokyo, Japan
| | - K Oba
- University of Tokyo, Department of Biostatistics, Division of Health Sciences and Nursing Graduate School of Medicine, Tokyo, Japan
| | - Y Matsuyama
- University of Tokyo, Department of Biostatistics, Division of Health Sciences and Nursing Graduate School of Medicine, Tokyo, Japan
| | | |
Collapse
|
13
|
Takahashi M, Munemoto Y, Nakamura M, Kotaka M, Kuroda H, Kato T, Minagawa N, Noura S, Fukunaga M, Kuramochi H, Touyama T, Takahashi T, Akagi Y, Satake H, Kurosawa S, Miura T, Mishima H, Sakamoto J, Oba K, Nagata N. SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy150.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Yamazaki K, Yasui H, Yamaguchi K, Kagawa Y, Kuboki Y, Yoshino T, Gamoh M, Komatsu Y, Satake H, Goto M, Tanioka H, Oki E, Kotaka M, Makiyama A, Denda T, Soeda J, Shibya K, Iwata M, Oba K, Kato T. A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Kato T, Satake H, Oba K, Kagawa Y, Yasui H, Nakamura M, Watanabe T, Matsumoto T, Hirata K, Muro K, Komatsu Y, Yoshino T, Yamazaki K, Mishima H, Kotaka M, Tsuji A, Kakeji Y, Oki E, Nagata N, Sakamoto J. Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Iwanaga I, Nakamura M, Eto K, Okuda H, Abe M, Aonuma A, Abe N, Sato A, Nakatsumi H, Muranaka T, Yagisawa M, Oba K, Sakata Y, Sakamoto N, Komatsu Y. HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx660.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Aoyama T, Oba K, Honda M, Sadahiro S, Hamada C, Mayanagi S, Kanda M, Maeda H, Sakamoto J, Saji S, Yoshikawa T. Clinical impact of postoperative surgical complications on the colorectal cancer survival and recurrence: Analyses of pooled individual patients’ data from three large phase III randomized trials. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx659.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Yamaguchi K, Komatsu Y, Oki E, Yoshino T, Yamazaki K, Shibuya K, Oba K, Kato T. APOLLON study: a phase I/II study for the safety and efficacy of panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Nagata N, Mishima H, Kurosawa S, Oba K, Sakamoto J. P-276 Safety and Efficacy of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Patients with Chemotherapy-Naïve Metastatic Colorectal Cancer (SAPPHIRE). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Iwamoto S, Hazama S, Kin H, Takemoto H, Kobayashi K, Takahashi Y, Kobayashi M, Maeda H, Nagata N, Oba K, Sakamoto J, Mishima H. P-157 A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Nagata N, Mishima H, Kurosawa S, Oba K, Sakamoto J. 228TiP Safety and efficacy of mFOLFOX6 + panitumumab combination therapy and 5-FU/LV + panitumumab combination therapy in patients with chemotherapy-naïve metastatic colorectal cancer (SAPPHIRE). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Yuki S, Komatsu Y, Nakatsumi H, Muranaka T, Kobayashi Y, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Fukushima H, Hisai H, Abe R, Sakamoto N, Oba K, Sakata Y. 157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Kono M, Odani T, Hiura K, Fukaya S, Oba K, Takeda T, Kikuchi H, Iwaki-Egawa S, Atsumi T. AB0293 High Serum Levels of Anti-Cyclic Citrullinated Peptide Antibody and Matrix Metalloproteinase-3 at the Time of Diagnosis of Rheumatoid Arthritis Are Possible Predictors of Future Initiation of Biological Agents. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
24
|
Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 2015; 26:1427-33. [PMID: 25908603 PMCID: PMC4478977 DOI: 10.1093/annonc/mdv197] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2015] [Accepted: 04/15/2015] [Indexed: 11/13/2022] Open
Abstract
EAGLE was a randomized, multicenter phase III study which evaluated the superiority of bevacizumab 10 mg/kg plus FOLFIRI compared with bevacizumab 5 mg/kg plus FOLFIRI in patients with mCRC previously treated with first-line bevacizumab plus an oxaliplatin-based regimen. The results suggest that the higher 10 mg/kg dose offers no clear clinical benefit compared with bevacizumab 5 mg/kg in this setting. Background A targeted agent combined with chemotherapy is the standard treatment in patients with metastatic colorectal cancer (mCRC). The present phase III study was conducted to compare two doses of bevacizumab combined with irinotecan, 5-fluorouracil/leucovorin (FOLFIRI) in the second-line setting after first-line therapy with bevacizumab plus oxaliplatin-based therapy. Patients and methods Patients were randomly assigned to receive FOLFIRI plus bevacizumab 5 or 10 mg/kg in 2-week cycles until disease progression. The primary end point was progression-free survival (PFS), and secondary end points included overall survival (OS), time to treatment failure (TTF), and safety. Results Three hundred and eighty-seven patients were randomized between September 2009 and January 2012 from 100 institutions in Japan. Baseline patient characteristics were well balanced between the two groups. Efficacy was evaluated in 369 patients (5 mg/kg, n = 181 and 10 mg/kg, n = 188). Safety was evaluated in 365 patients (5 mg/kg, n = 180 and 10 mg/kg, n = 185). The median PFS was 6.1 versus 6.4 months (hazard ratio, 0.95; 95% confidence interval [CI] 0.75–1.21; P = 0.676), and median TTF was 5.2 versus 5.2 months (hazard ratio, 1.01; 95% CI 0.81–1.25; P = 0.967), respectively, for the bevacizumab 5 and 10 mg/kg groups. Follow-up of OS is currently ongoing. Adverse events, including hypertension and hemorrhage, occurred at similar rates in both groups. Conclusion Bevacizumab 10 mg/kg plus FOLFIRI as the second-line treatment did not prolong PFS compared with bevacizumab 5 mg/kg plus FOLFIRI in patients with mCRC. If bevacizumab is continued after first-line therapy in mCRC, a dose of 5 mg/kg is appropriate for use as second-line treatment. Clinical trial identifier UMIN000002557.
Collapse
Affiliation(s)
- S Iwamoto
- Department of Surgery, Kansai Medical University Hirakata Hospital, Hirakata
| | - T Takahashi
- Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu
| | - H Tamagawa
- Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka
| | - M Nakamura
- Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto
| | - Y Munemoto
- Department of Surgery, Fukuiken Saiseikai Hospital, Fukui
| | - T Kato
- Department of Surgery, Kansai Rosai Hospital, Amagasaki
| | - T Hata
- Department of Surgery, Osaka University, Suita
| | - T Denda
- Department of Gastroenterology, Chiba Cancer Center, Chiba
| | - Y Morita
- Department of Radiology, Kobe Medical Center, Kobe
| | - M Inukai
- Department of Integrated Medicine, Kagawa University, Kita
| | - K Kunieda
- Department of Surgery, Gifu Prefectural General Medical Center, Gifu
| | - N Nagata
- Department of Surgery, Kitakyushu General Hospital, Kitakyusyu
| | - K Kurachi
- Second Department of Surgery, Hamamatsu University School of Medicine, Shizuoka
| | - K Ina
- Department of Medical Oncology, Nagoya Memorial Hospital, Nagoya
| | - M Ooshiro
- Department of Surgery, Toho University Medical Center Sakura Hospital, Sakura
| | - T Shimoyama
- Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo
| | - H Baba
- Department of Gastroenterological Surgery, Kumamoto University, Kumamoto
| | - K Oba
- Department of Biostatistics, School of Public Health, Graduate School of Medicine and Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo
| | | | - H Mishima
- Cancer Center, Aichi Medical University, Nagakute, Japan
| |
Collapse
|
25
|
Affiliation(s)
- T Serizawa
- Biological Science Research Center, Lion Corporation, Kanagawa, Japan
| | | | | |
Collapse
|
26
|
Nakamura M, Kobayashi Y, Yuki S, Nakatsumi H, Hayashi H, Iwanaga I, Tsuji Y, Hatanaka K, Okuda H, Konno J, Yamamoto F, Iwai K, Onodera M, Takagi T, Hisai H, Koike M, Abe R, Oba K, Sakata Y, Komatsu Y. Randomized Controlled Trial on the Skin Toxicity of Panitumumab in Third Line Treatment of Kras Wild-Type Metastatic Colorectal Cancer: Hgcsg1001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-Stepp): Additional Analysis of Qol and Skin Toxicity. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.54] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Munemoto Y, Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Oshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H. A Phase III Study of Eagle Comparing Two Doses of Bevacizumab Combined with Folfiri in the Second-Line Setting After First-Line Treatment with Bevacizumab Plus Oxaliplatin-Based Therapy : Kras Subgroup Findings. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Kono M, Yasuda S, Kato M, Kanetsuka Y, Kurita T, Fujieda Y, Otomo K, Horita T, Oba K, Kondo M, Mukai M, Yanai M, Fukasawa Y, Atsumi T. Long-term outcome in Japanese patients with lupus nephritis. Lupus 2014; 23:1124-32. [PMID: 24860121 DOI: 10.1177/0961203314536246] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The objective of this study was to clarify the long-term outcome in patients with lupus nephritis (LN) according to the International Society of Nephrology and Renal Pathology Society classification. This retrospective analysis comprised 186 Japanese patients given a diagnosis of LN by renal specimen with a mean observation period of 12 years. Primary end point was defined as death or end-stage renal disease, and standardized mortality ratios were calculated. Five patients presented with histopathological class I, 62 with II, 21 with III or III+V, 73 with IV or IV+V and 25 with V. Fourteen deaths occurred, corresponding to an overall standardized mortality ratio of 3.59 (95% confidence interval 2.02-5.81, p < 0.0001). Kaplan-Meier analysis revealed a 10-year overall survival of 95.7%. Nephrotic proteinuria (≥3.5 g/day) at baseline was identified as an independent poor prognostic factor for overall survival in Cox regression analysis. Kaplan-Meier analysis revealed a 10-year renal survival as 94.3%. Male gender and nephrotic proteinuria at baseline were identified as independent poor prognostic factors for renal survival in Cox regression analysis. In conclusion, LN was associated with a 3.59-fold increase in mortality compared with the general population. Male gender and nephrotic proteinuria were predictive for poor renal outcome.
Collapse
Affiliation(s)
- M Kono
- Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - S Yasuda
- Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - M Kato
- Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Y Kanetsuka
- Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - T Kurita
- Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Y Fujieda
- Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - K Otomo
- Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - T Horita
- Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - K Oba
- Translational Research and Clinical Trial Center, Hokkaido University Hospital, Sapporo, Japan
| | - M Kondo
- Department of Rheumatology, Sapporo City General Hospital, Sapporo, Japan
| | - M Mukai
- Department of Rheumatology, Sapporo City General Hospital, Sapporo, Japan
| | - M Yanai
- Department of Pathology, Sapporo City General Hospital, Sapporo, Japan
| | - Y Fukasawa
- Department of Pathology, Sapporo City General Hospital, Sapporo, Japan
| | - T Atsumi
- Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| |
Collapse
|
29
|
Tanaka J, Morishima Y, Takahashi Y, Yabe T, Oba K, Takahashi S, Taniguchi S, Ogawa H, Onishi Y, Miyamura K, Kanamori H, Aotsuka N, Kato K, Kato S, Atsuta Y, Kanda Y. Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. Blood Cancer J 2013; 3:e164. [PMID: 24292416 PMCID: PMC3880445 DOI: 10.1038/bcj.2013.62] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Accepted: 10/29/2013] [Indexed: 01/08/2023] Open
Abstract
To clarify the effect of killer cell immunoglobulin-like receptor (KIR) ligand incompatibility on outcomes of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients in complete remission after single cord blood transplantation (CBT), we assessed the outcomes of CBT registered in the Japan Society for Hematopoietic Cell Transplantation (JSHCT) database. A total of 643 acute leukemia (357 AML and 286 ALL) patient and donor pairs were categorized according to their KIR ligand incompatibility by determining whether or not they expressed HLA-C, Bw4 or A3/A11 by DNA typing. A total of 128 patient–donor pairs were KIR ligand-incompatible in the graft-versus-host (GVH) direction and 139 patient–donor pairs were incompatible in the host-versus-graft (HVG) direction. Univariate and multivariate analyses showed no significant differences between the KIR ligand-incompatible and compatible groups in the GVH direction for both AML and ALL patients of overall survival, disease-free survival, relapse incidence, non-relapse mortality and acute GVH disease. However, KIR incompatibility in the HVG direction ameliorated engraftment in ALL patients (hazard ratio 0.66, 95% confidence interval 0.47–0.91, P=0.013). Therefore, there were no effects of KIR ligand incompatibility in the GVH direction on single CBT outcomes for acute leukemia patients without anti-thymocyte globulin use. However, it is necessary to pay attention to KIR incompatibility in the HVG direction for engraftment.
Collapse
Affiliation(s)
- J Tanaka
- Depatment of Hematology, Tokyo Women's Medical University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Okada A, Oba K, Ichinose N, Shibazaki T, Yokozawa T, Oda T. P227 Effect on infectious diseases practice and antimicrobial stewardship of one infectious diseases doctor at a community hospital. Int J Antimicrob Agents 2013. [DOI: 10.1016/s0924-8579(13)70468-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Kurita T, Yasuda S, Oba K, Otomo K, Shida H, Watanabe T, Kanetsuka Y, Kono M, Odani T, Fujieda Y, Kon Y, Horita T, Sato N, Atsumi T. THU0231 The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
32
|
Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Eto T, Nakamae H, Minagawa K, Miyamura K, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishimoto N, Oba K, Masauzi N. Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Bone Marrow Transplant 2013; 48:1389-94. [PMID: 23665820 DOI: 10.1038/bmt.2013.68] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2012] [Revised: 03/05/2013] [Accepted: 04/08/2013] [Indexed: 11/09/2022]
Abstract
In this study, outcomes for 575 adult ALL patients aged ≥45 years who underwent first allo-SCT in CR were analyzed according to the type of conditioning regimen (myeloablative conditioning (MAC) for 369 patients vs reduced-intensity conditioning (RIC) for 206 patients). Patients in the RIC group were older (median age, 58 vs 51 years, P<0.0001). There were no statistically significant differences in 3-year OS, disease-free survival (DFS) and non-relapse mortality (NRM): 51% vs 53%, 47% vs 39% and 38% vs 36%, respectively. Multivariate analysis showed that CR2 and HLA mismatching were associated with poor OS (P=0.002 and P=0.019, respectively). HLA mismatching was associated with lower rate of relapse (P=0.016), but was associated with higher rate of NRM (P=0.001). RIC was associated with good OS and DFS in patients who received HLA-mismatch transplantation and were aged ≥55 years compared with MAC by multivariate analysis for each event with interaction (hazard ratio (HR) and 95% confidence interval 0.35 and 0.15-0.81, P=0.014 for OS and 0.36 and 0.16-0.81, P=0.013 for DFS). Therefore, patients ≥55 years of age with HLA-mismatch transplantation should be candidates for RIC rather than MAC.
Collapse
Affiliation(s)
- J Tanaka
- Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Ouchi M, Oba K, Yamashita H, Okazaki M, Tsunoda M, Ohara M, Sekimizu K, Watanabe K, Suzuki T, Nakano H. Effects of sex and age on serum 1,5-anhydroglucitol in nondiabetic subjects. Exp Clin Endocrinol Diabetes 2012; 120:288-95. [PMID: 22421984 DOI: 10.1055/s-0032-1304604] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The aim of this study was to demonstrate the effects of sex and age on serum levels of 1,5-AG in nondiabetic subjects.A total of 1 134 nondiabetic subjects aged 16-96 years with HbA1c less than 6.8% were recruited and divided into 4 HbA1c groups (Q1: HbA1c≤5.3; Q2: 5.4-5.8; Q3: 5.9-6.3; and Q4: 6.4-6.8 [%]). 38 elderly subjects (65 years or older) in the Q3 and Q4 groups (13 men and 25 women) underwent a 75-g oral glucose tolerance test (OGTT).The Q4 group had significantly lower 1,5-AG levels than did the Q1 group among nonelderly males, nonelderly females, and elderly men. In elderly women, 1,5-AG levels did not differ among the 4 HbA1c groups. In both nonelderly and elderly subjects, the 1,5-AG level of the Q1 group was significantly higher in males than in females. Stepwise multivariate regression analysis showed that age was significantly associated with 1,5-AG level in both sexes. HbA1c was significantly associated with the 1,5-AG level in males, while there was no significant association between HbA1c and the 1,5-AG level in females. In the elderly OGTT group, although the glucose levels of both sexes during OGTT were identical, the mean urinary glucose levels and the percentages of subjects with glucosuria were significantly higher in elderly men than in elderly women.Serum 1,5-AG levels were significantly associated with age and sex. The sensitivity of the 1,5-AG level for identifying postprandial hyperglycemia in elderly women with near-normoglycemia is less reliable because they have a higher renal threshold for glucose.
Collapse
Affiliation(s)
- M Ouchi
- Department of Internal Medicine, Division of Cardiology, Hepatology, Geriatrics, and Integrated Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Miyashita Y, Morita S, Oba K, Buyse ME, Macdonald JS, Sakamoto J. SAMIT: Preliminary safety data from a 2x2 factorial randomized phase III trial to investigate weekly paclitaxel (PTX) followed by oral fluoropyrimidines (FPs) versus FPs alone as adjuvant chemotherapy in patients (pts) with gastric cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Shinohara N, Maruyama S, Abe T, Sazawa A, Kamai T, Takahashi M, Tatsugami K, Yokoi S, Kanayama H, Deguchi T, Naito S, Oba K, Nonomura K. A novel prognostic classification for overall survival in Japanese patients with untreated metastatic renal cell carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Nagata N, Kondo K, Kato T, Shibata Y, Okuyama Y, Ikenaga M, Tanemura H, Oba K, Nakao A, Sakamoto J, Mishima H. Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study. Hepatogastroenterology 2009; 56:1346-1353. [PMID: 19950789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
BACKGROUND/AIMS This study assessed the efficacy and toxicity of the FOLFOX4 (SWIFT1) and mFOLFOX6 (SWIFT2) regimens in Japanese patients with metastatic colorectal cancer (mCRC). METHODOLOGY Patients with mCRC were required to have ECOG performance status of 0 to 1, and to have adequate organ function. Two multicenter Phase II studies (SWIFT1/SWIFT2) were conducted in chemotherapy naive patients with mCRC. RESULTS 112 patients were enrolled in these studies (SWIFT1: 54 patients / SWIFT2: 58 patients). The disease sites for each study were the colon in 27 patients and 28 patients, and the rectum in 27 patients and 30 patients, respectively. All patients received a median of 8 courses. After a median follow-up period of 35 months, 54 patients and 58 patients were evaluable in the respective studies, and the overall response rate was 50.0% (CR:31 PR:53). The response rate according to the sites of metastasis were as follows: liver, 54.1% (46/85); lung, 17.4% (4/23); and lymph node, 23.3% (7/30). Grade 3/4 neutropenia occurred in 14 patients (12.5%), while Grade 3/4 non-hematological toxicities were observed in 16 patients (31.0%) and Grade 3 neurotoxicity was observed in 6patients (5.4%) and 5 patients (4.5%), respectively. CONCLUSIONS FOLFOX4 (SWIFT1) and mFOLFOX6 (SWIFT2) regimens complying with the international standard dosage and schedule can also be administered safely and effectively in Japan.
Collapse
Affiliation(s)
- N Nagata
- Kitakyushu General hospital, Kitakyushu, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Watanabe K, Ouchi M, Suzuki K, Futami-Suda S, Suzuki T, Nakano H, Oba K. Abstract: P910 VASCULAR ENDOTHELIAL FUNCTION IS CLOSELY RELATED TO GLUCOSE METABOLISM IN HEALTHY JAPANESE SUBJECTS. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71031-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
38
|
Oba K, Morita S, Tsuburaya A, Kodera Y, Kobayashi M, Sakamoto J. Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan. J Chemother 2008; 18:311-7. [PMID: 17129844 DOI: 10.1179/joc.2006.18.3.311] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Adjuvant chemotherapy for gastric cancer has been extensively explored in Japan since the 1950s, and a combination of oral fluorinated pyrimidines (o-FP) and mitomycin C (MMC) has been mainly utilized for adjuvant chemotherapy. However, there is no sufficient evidence for the efficacy of adjuvant therapy. Therefore, we assessed the efficacy of o-FPs over surgery alone (control) by means of a meta-analysis of Japanese centrally randomized controlled clinical trials conducted between 1980 and 2005. For inclusion in this study, studies had to compare adjuvant chemotherapy for curatively resected gastric cancer with surgery alone, mainly targeting o-FP, and central randomization designed to comply with contemporary standards for clinical trials in Japan. For the 4 trials that met the eligibility criteria, the estimated hazard ratio was 0.73 (95%CI=0.60-0.89). Our findings show that in Japan adjuvant chemotherapy using o-FP for long-term maintenance therapy appears to be effective for gastric cancer patients after curative resection.
Collapse
Affiliation(s)
- K Oba
- Department of Epidemiological & Clinical Research Information Management, Kyoto University Graduate School of Medicine, Kyoto, Japan.
| | | | | | | | | | | |
Collapse
|
39
|
|
40
|
Ninomiya M, Kondo K, Matsuo K, Hirabayashi N, Kojima H, Kobayashi M, Kawamura S, Ando T, Musha N, Konno H, Nagata N, Usuki H, Miyashita Y, Oba K, Morita S, Sakamoto J. Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. J Chemother 2007; 19:444-50. [PMID: 17855190 DOI: 10.1179/joc.2007.19.4.444] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The aim of this study was to investigate the efficacy and safety of combination chemotherapy with weekly paclitaxel and 5-fluorouracil (5-FU) as first-line treatment in patients with advanced or recurrent gastric carcinoma. A total of 65 patients were treated with the following regimen, administered every 28 days; 5-FU 600 mg/m2 by 24-hour continuous infusion from days 1 through 5, and weekly paclitaxel 80 mg/m2 by 3-hour intravenous infusion on days 8, 14, and 21. A total of 272 cycles were conducted with a median of 4 (2-13) cycles per case. Out of 57 patients with measurable disease by RECIST criteria, there were 2 complete responses (3.5%), 20 partial responses (35.1%) and 25 cases with stable disease (43.9%). The overall response rate was 38.6% (95%CI: 26.0-51.2%). The median survival time and 1-year survival rates were 329 days and 47.4%, respectively. Both hematologic and non-hematologic toxicities were well tolerated.
Collapse
Affiliation(s)
- M Ninomiya
- Department of Surgery, Hiroshima City Hospital, Hiroshima, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Oba K, Morita S, Matsui T, Kobayashi M, Kondo K, Sakamoto J. An individual patient data meta-analysis of the immunochemotherapy using lentinan in patients with advanced gastric cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15136] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15136 Background: An anti-tumor effect of lentinan (LNT), a non-specific immunomodulator, via an immunological response has been reported and combination immunochemotherapy has been examined. However, the survival benefit of LNT for patients with advanced or recurrent gastric cancer (AGC) was unclear in the world. We performed an individual patient data (IPD) meta-analysis in order to evaluate the survival effect of immunochemotherapy using LNT. Methods: A computerized and a manual search procedure were performed to identify all randomized clinical trial (RCT) for chemotherapy in patients (pts) with AGC. Inclusion criteria were RCTs for AGC and to compare any chemotherapy (control group) with the same plus LNT (LNT group). The primary endpoint was overall survival, secondary endpoints includes objective tumor response and toxicity. All analyses were based on IPD. Treatment effects were displayed as hazard ratios estimated by Cox proportional hazard model. A ratio less than unity indicated benefit from LNT. Results: We analyzed IPD of 5 randomized clinical trials for AGC, which met the predetermined inclusion criteria. These 5 trials had a combined total of 650 pts (LNT: 339 pts median age=63, control: 311 pts median age=63). The number of deaths was 83.8% (286/334) in LNT group and 84.8% (262/309) in control group. The overall hazard ratio was 0.83 (95%CI, 0.70–0.98; p=0.03) with no significant heterogeneity between the treatment effects in different trials (χ2 for heterogeneity=3.69; p=0.45). Three hundred and fifty five pts were evaluable for objective tumor response and the response rate was 18.4% (21/185) in LNT group (CR, 0 pts; PR, 21 pts) and 6.3% (5/173) in control (CR, 0 pts; PR, 5 pts). There were no significant differences in the toxicity. Conclusions: This IPD meta-analysis demonstrated that LNT significantly improves both OS and tumor response in pts with AGC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Oba
- Kyoto University, Kyoto, Japan; Nagoya University, Nagoya, Japan; Prefectural Aichi Hospital, Okazaki, Japan; Kochi University, Kochi, Japan; Nagoya Medical Center, Nagoya, Japan
| | - S. Morita
- Kyoto University, Kyoto, Japan; Nagoya University, Nagoya, Japan; Prefectural Aichi Hospital, Okazaki, Japan; Kochi University, Kochi, Japan; Nagoya Medical Center, Nagoya, Japan
| | - T. Matsui
- Kyoto University, Kyoto, Japan; Nagoya University, Nagoya, Japan; Prefectural Aichi Hospital, Okazaki, Japan; Kochi University, Kochi, Japan; Nagoya Medical Center, Nagoya, Japan
| | - M. Kobayashi
- Kyoto University, Kyoto, Japan; Nagoya University, Nagoya, Japan; Prefectural Aichi Hospital, Okazaki, Japan; Kochi University, Kochi, Japan; Nagoya Medical Center, Nagoya, Japan
| | - K. Kondo
- Kyoto University, Kyoto, Japan; Nagoya University, Nagoya, Japan; Prefectural Aichi Hospital, Okazaki, Japan; Kochi University, Kochi, Japan; Nagoya Medical Center, Nagoya, Japan
| | - J. Sakamoto
- Kyoto University, Kyoto, Japan; Nagoya University, Nagoya, Japan; Prefectural Aichi Hospital, Okazaki, Japan; Kochi University, Kochi, Japan; Nagoya Medical Center, Nagoya, Japan
| |
Collapse
|
42
|
Sakamoto J, Hamada C, Yoshida S, Kodaira S, Yasutomi M, Kato T, Oba K, Nakazato H, Saji S, Ohashi Y. An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer 2007; 96:1170-7. [PMID: 17375049 PMCID: PMC2360162 DOI: 10.1038/sj.bjc.6603686] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Uracil–Tegafur (UFT), an oral fluorinated pyrimidine chemotherapeutic agent, has been used for adjuvant chemotherapy in curatively resected colorectal cancer patients. Past trials and meta-analyses indicate that it is somewhat effective in extending survival of patients with rectal cancer. The objective of this study was to perform a reappraisal of randomised clinical trials conducted in this field. We designed an individual patient-based meta-analysis of relevant clinical trials to examine the benefit of UFT for curatively resected rectal cancer in terms of overall survival (OS), disease-free survival (DFS), and local relapse-free survival (LRFS). We analysed individual patient data of five adjuvant therapy randomised clinical trials for rectal cancer, which met the predetermined inclusion criteria. These five trials had a combined total of 2091 patients, UFT as adjuvant chemotherapy compared to surgery-alone, 5-year follow-up, intention-to-treat-based analytic strategy, and similar endpoints (OS and DFS). In a pooled analysis, UFT had significant advantage over surgery-alone in terms of both OS (hazard ratio, 0.82; 95% confidence interval (CI), 0.70–0.97; P=0.02) and DFS (hazard ratio, 0.73; 95%CI, 0.63–0.84; P<0.0001). This individual patient-based meta-analysis demonstrated that oral UFT significantly improves both OS and DFS in patients with curatively resected rectal cancer.
Collapse
Affiliation(s)
- J Sakamoto
- Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum, Kyoto University, Graduate School of Medicine, Kyoto, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Oba K, Teramukai S, Kobayashi M, Matsui T, Nakazato H, Ito K, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide k (PSK) for patients with curatively resected gastric cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14038 Background: An anti-tumor effect of non-specific immunomodulators, mainly PSK and OK-432, via an immunological response has been reported and combination immunochemotherapy has been examined. However, the survival benefit of immunochemotherapy for patients with curatively resected gastric cancer was unclear in the world. We performed a meta-analysis in order to evaluate the survival effect of immunochemotherapy employing a biological response modifier Polysaccharide K (PSK) in Japan. Methods: We reassessed by means of meta-analysis of data with central randomization from 5164 patients enrolled in Japanese eight clinical trials. In all eight trials patients were followed up for at least 5 years after surgery and enrollment of the last patient and outcomes for standard chemotherapy were compared with those for chemotherapy plus PSK. The endpoint was 5-year survival odds ratio. Data were analyzed by using a weighted average of the log odds ratios (using Peto’s method). Results: The 5-year odds ratio for all eligible patients was 0.88 (95% confidence interval: 0.78–0.98; p=0.021). There was a significant heterogeneity between the trials (p=0.016). Conclusions: The results of this meta-analysis suggest that adjuvant immunochemotherapy with PSK can improve survival of patients with curatively resected gastric cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Oba
- Kyoto University, Kyoto, Japan; Kochi University, Nangoku, Japan; Aichi Cancer Center, Okazaki, Japan; Yokoyama Intestinal Gastric Hospital, Nagoya, Japan; Nagoya University, Nagoya, Japan
| | - S. Teramukai
- Kyoto University, Kyoto, Japan; Kochi University, Nangoku, Japan; Aichi Cancer Center, Okazaki, Japan; Yokoyama Intestinal Gastric Hospital, Nagoya, Japan; Nagoya University, Nagoya, Japan
| | - M. Kobayashi
- Kyoto University, Kyoto, Japan; Kochi University, Nangoku, Japan; Aichi Cancer Center, Okazaki, Japan; Yokoyama Intestinal Gastric Hospital, Nagoya, Japan; Nagoya University, Nagoya, Japan
| | - T. Matsui
- Kyoto University, Kyoto, Japan; Kochi University, Nangoku, Japan; Aichi Cancer Center, Okazaki, Japan; Yokoyama Intestinal Gastric Hospital, Nagoya, Japan; Nagoya University, Nagoya, Japan
| | - H. Nakazato
- Kyoto University, Kyoto, Japan; Kochi University, Nangoku, Japan; Aichi Cancer Center, Okazaki, Japan; Yokoyama Intestinal Gastric Hospital, Nagoya, Japan; Nagoya University, Nagoya, Japan
| | - K. Ito
- Kyoto University, Kyoto, Japan; Kochi University, Nangoku, Japan; Aichi Cancer Center, Okazaki, Japan; Yokoyama Intestinal Gastric Hospital, Nagoya, Japan; Nagoya University, Nagoya, Japan
| | - J. Sakamoto
- Kyoto University, Kyoto, Japan; Kochi University, Nangoku, Japan; Aichi Cancer Center, Okazaki, Japan; Yokoyama Intestinal Gastric Hospital, Nagoya, Japan; Nagoya University, Nagoya, Japan
| |
Collapse
|
44
|
Sakamoto J, Tsuburaya A, Morita S, Matsui T, Oba K, Kodera Y, Kobayashi M, Yoshida K, Nakao A. Adjuvant chemotherapy with tegafur/uracil (UFT) for gastric cancer. A meta-analysis of centrally randomized clinical trials. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4033] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4033 Background: A consensus regarding standard adjuvant chemotherapy for curatively resected gastric cancer has not been obtained between Japan and Western world. In order to evaluate the effect of UFT which is the most frequently used in Japan over surgery alone control, a meta-analysis was performed investigating 4 clinical trials. Methods: After meticulous examination of each trial, trials with improper randomization using envelop method were excluded from the analysis. A total of 1503 patients, enrolled in four relevant trials (JCOG 8401, JCOG 8801, JCOG9206–2, and NSAS-GC) using UFT for chemotherapy and performed by central randomization, were determined eligible for the meta-analysis. The endpoint was overall survival and intent-to treat analysis was implemented. Results: The 5-year overall survival odds ratio was 0.70 (95%CI; 0.54–0.89). The treatment effect of oral UFT was shown to be statistically significant (p=0.01) over surgery alone therapy (n=1251). No significant heterogeneity between the trials was demonstrated (p=0.365). The 5-year overall survival odds ratio was 0.71(95%CI; 0.54–0.92). Conclusions: From these results of the present meta-analysis, it is strongly suggested that chemotherapy after surgery with UFT, can improve survival of the patients with curatively resected gastric cancer, and UFT should be considered as the standard postoperative adjuvant treatment for gastric cancer in Japan, where extensive gastrectomy with D2 lymph node dissection is implemented as a routine surgical procedure. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Sakamoto
- Kyoto University Graduate School of Medicine, Kyoto, Japan; Kanagawa Cancer Center, Yokohama, Japan; Kyoto University, Kyoto, Japan; Aichi Cancer Center, Okazaki, Japan; Nagoya University, Nagoya, Japan; Kochi University, Nangoku, Japan; Hiroshima University, Hiroshima, Japan
| | - A. Tsuburaya
- Kyoto University Graduate School of Medicine, Kyoto, Japan; Kanagawa Cancer Center, Yokohama, Japan; Kyoto University, Kyoto, Japan; Aichi Cancer Center, Okazaki, Japan; Nagoya University, Nagoya, Japan; Kochi University, Nangoku, Japan; Hiroshima University, Hiroshima, Japan
| | - S. Morita
- Kyoto University Graduate School of Medicine, Kyoto, Japan; Kanagawa Cancer Center, Yokohama, Japan; Kyoto University, Kyoto, Japan; Aichi Cancer Center, Okazaki, Japan; Nagoya University, Nagoya, Japan; Kochi University, Nangoku, Japan; Hiroshima University, Hiroshima, Japan
| | - T. Matsui
- Kyoto University Graduate School of Medicine, Kyoto, Japan; Kanagawa Cancer Center, Yokohama, Japan; Kyoto University, Kyoto, Japan; Aichi Cancer Center, Okazaki, Japan; Nagoya University, Nagoya, Japan; Kochi University, Nangoku, Japan; Hiroshima University, Hiroshima, Japan
| | - K. Oba
- Kyoto University Graduate School of Medicine, Kyoto, Japan; Kanagawa Cancer Center, Yokohama, Japan; Kyoto University, Kyoto, Japan; Aichi Cancer Center, Okazaki, Japan; Nagoya University, Nagoya, Japan; Kochi University, Nangoku, Japan; Hiroshima University, Hiroshima, Japan
| | - Y. Kodera
- Kyoto University Graduate School of Medicine, Kyoto, Japan; Kanagawa Cancer Center, Yokohama, Japan; Kyoto University, Kyoto, Japan; Aichi Cancer Center, Okazaki, Japan; Nagoya University, Nagoya, Japan; Kochi University, Nangoku, Japan; Hiroshima University, Hiroshima, Japan
| | - M. Kobayashi
- Kyoto University Graduate School of Medicine, Kyoto, Japan; Kanagawa Cancer Center, Yokohama, Japan; Kyoto University, Kyoto, Japan; Aichi Cancer Center, Okazaki, Japan; Nagoya University, Nagoya, Japan; Kochi University, Nangoku, Japan; Hiroshima University, Hiroshima, Japan
| | - K. Yoshida
- Kyoto University Graduate School of Medicine, Kyoto, Japan; Kanagawa Cancer Center, Yokohama, Japan; Kyoto University, Kyoto, Japan; Aichi Cancer Center, Okazaki, Japan; Nagoya University, Nagoya, Japan; Kochi University, Nangoku, Japan; Hiroshima University, Hiroshima, Japan
| | - A. Nakao
- Kyoto University Graduate School of Medicine, Kyoto, Japan; Kanagawa Cancer Center, Yokohama, Japan; Kyoto University, Kyoto, Japan; Aichi Cancer Center, Okazaki, Japan; Nagoya University, Nagoya, Japan; Kochi University, Nangoku, Japan; Hiroshima University, Hiroshima, Japan
| |
Collapse
|
45
|
Nakano H, Oba K, Saito Y, Ouchi M, Yamashita N, Okamura K, Takai E, Mizuno S, Matsumura N, Inuzuka Y, Suzuki T. Asymptomatic Pyuria in Diabetic Women. J Urol 2006. [DOI: 10.1016/s0022-5347(05)00551-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- H. Nakano
- Division of Geriatric Medicine, Nippon Medical School, Tokyo, Japan
| | - K. Oba
- Division of Geriatric Medicine, Nippon Medical School, Tokyo, Japan
| | - Y. Saito
- Division of Geriatric Medicine, Nippon Medical School, Tokyo, Japan
| | - M. Ouchi
- Division of Geriatric Medicine, Nippon Medical School, Tokyo, Japan
| | - N. Yamashita
- Division of Geriatric Medicine, Nippon Medical School, Tokyo, Japan
| | - K. Okamura
- Division of Geriatric Medicine, Nippon Medical School, Tokyo, Japan
| | - E. Takai
- Division of Geriatric Medicine, Nippon Medical School, Tokyo, Japan
| | - S. Mizuno
- Division of Geriatric Medicine, Nippon Medical School, Tokyo, Japan
| | - N. Matsumura
- Division of Geriatric Medicine, Nippon Medical School, Tokyo, Japan
| | - Y. Inuzuka
- Division of Geriatric Medicine, Nippon Medical School, Tokyo, Japan
| | - T. Suzuki
- Division of Geriatric Medicine, Nippon Medical School, Tokyo, Japan
| |
Collapse
|
46
|
Matsuyama H, Pan Y, Oba K, Yoshihiro S, Matsuda K, Hägarth L, Kudren D, Naito K, Bergerheim USR, Ekman P. The role of chromosome 8p22 deletion for predicting disease progression and pathological staging in prostate cancer. Aktuelle Urol 2003; 34:247-9. [PMID: 14566675 DOI: 10.1055/s-2003-41607] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The natural course of human prostate cancer is highly variable, and we still lack reliable tools to predict the patient's outcome. Recent publications suggest that the deletion of chromosome 8p22 has an important role for tumor progression in prostate cancer. Totally, 97 patients (41 Japanese and 56 Swedish) were studied to detect the status of chromosome 8p22 deletion by the fluorescence in situ hybridization (FISH) technique. Seventy-seven underwent surgery (59 radical prostatectomies or 18 lymph node dissections), and the specimens were prepared by touch biopsy. Fine-needle aspiration biopsies (FNAB) were obtained from another non-operative 20 cases. Disease progression was evaluated in 57 patients with a median follow-up of 59 months. 8p22 deletions were detected in 58 (60 %) of all cases. The frequency of 8p22 deletion did not significantly differ between different preparations of specimens (touch biopsy vs. FNAB) as well as between different races (Japanese vs. Swedish). Cases with more than pT3 tumors had a significantly higher frequency of 8p22 deletion than those with pT2 (p < 0.01). Multivariate analysis demonstrated that 8p22 deletion was the strongest parameter to predict disease progression (hazard ratio = 5.75; p = 0.0001). Studies on chromosomal deletions of 8p22 by the FISH technique may serve as a universal genetic marker to optimize the treatment strategy in patients with prostate cancer.
Collapse
Affiliation(s)
- H Matsuyama
- Department of Urology, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Yamaguchi S, Yoshihiro S, Matsuyama H, Nagao K, Fukunaga K, Matsumoto H, Matsuda K, Oba K, Naito K. The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma. Clin Genet 2003; 63:184-91. [PMID: 12694227 DOI: 10.1034/j.1399-0004.2003.00035.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
To explore the role of allelic losses at 3p25 and genetic alterations of chromosome 8, we investigated the relationships between genetic alterations in these chromosomal regions and clinicopathologic findings (such as tumor size and grade), by employing fluorescence in situ hybridization (FISH). Fifty Japanese clear-cell renal cell carcinomas (RCCs) were examined by dual-color FISH using cosmid DNA probes for 3p25.1-25.3 combined with probes for chromosome 3 centromere, 8p12, 8p21.1, 8p21.3, 8p22 and 8q24.12-24.13 (c-myc), and chromosome 8 centromere. Deletion at 3p25.1-25.3 was detected in 38 patients (76%), while 8p12 deletion, 8p21.1 deletion, 8p21.3 deletion, 8p22 deletion and c-myc gain were detected in 23 (46%), 25 (50%), 25 (50%), 25 (50%), and 20 patients (40%), respectively. There was a significant correlation between 8p21.1 deletion, 8p21.3 deletion and 8p21.1 deletion with c-myc gain and tumor grade (p = 0.04, 0.04 and 0.02, respectively). Deletions at 8p21.1 and 8p21.3 with 3p deletion were significantly related to tumor grade; the statistical significance was identical to that of sole 8p deletion with tumor grade. The deletion at 3p25.1-25.3 with c-myc gain showed a significant correlation with tumor size, indicating an association with tumor progression. Our results suggest that the allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell RCC.
Collapse
Affiliation(s)
- S Yamaguchi
- Department of Urology, Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Nakano H, Watanabe K, Okazaki K, Suzuki T, Oba K. 2P-0587 Effect of atorvastatin on hypersensitivity CRP in patients treated with natural statins. ATHEROSCLEROSIS SUPP 2003. [DOI: 10.1016/s1567-5688(03)90726-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
49
|
Suzuki T, Watanabe K, Okazaki K, Nakano H, Oba K. IP-0047 Relation between apo(a) lipoprotein phenotypes/relative lymphocyte count and ischaemic heart disease (IHD). ATHEROSCLEROSIS SUPP 2003. [DOI: 10.1016/s1567-5688(03)90122-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
50
|
Watanabe K, Okazaki K, Suzuki T, Oba K. 2P-0539 Intima-media thickness is related to inflammatory change of atherosclerosis. ATHEROSCLEROSIS SUPP 2003. [DOI: 10.1016/s1567-5688(03)90678-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|